Evidence map›Paper›PMID 41563477›Full record

GuidelineAnnals of hematology2026

Prevention, diagnosis and management of community acquired respiratory virus infections including COVID-19 in patients with cancer: 2025 updated evidence-based guideline of the infectious diseases working party (AGIHO) of the German society for hematology and medical oncology (DGHO).

Nicola Giesen, Sibylle C Mellinghoff, Elham Khatamzas, Felix Korell, Marcus Hentrich, Hermann Einsele, Larissa Henze, Claus Peter Heußel, Christian Hohmann, Björn-Erik Ole Jensen and 10 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Nicola GiesenDepartment of Hematology, Oncology and Palliative Care, Robert Bosch Hospital, Auerbachstr. 110, Stuttgart, 70376, Germany. nicola.giesen@rbk.de.
Sibylle C MellinghoffDepartment I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany.
Elham KhatamzasDepartment of Infectious Diseases and Tropical Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Felix KorellInternal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Marcus HentrichDepartment of Medicine III, Red Cross Hospital Munich, Munich, Germany.
Hermann EinseleDepartment of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Larissa HenzeDepartment of Medicine, Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Rostock, Germany.
Claus Peter HeußelDiagnostic and Interventional Radiology with Nuclear Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.
Christian HohmannDepartment of Medicine, Clinic I - Hematology, Oncology, Infectiology, Department of Intensive Care and Emergency Medicine, Klinikum Bremen-Mitte, Bremen, Germany.
Björn-Erik Ole JensenDepartment of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.
Malte B MoninDepartment of Internal Medicine I, University Hospital Bonn, Bonn, Germany.
Philippe SchafhausenDepartment of Oncology, Hematology, and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Enrico SchalkDepartment of Hematology, Oncology and Cell Therapy, Medical Faculty, Otto von Guericke University Magdeburg, Magdeburg, Germany.
Karsten SpiekermannDepartment of Medicine III, University Hospital LMU Munich, Munich, Germany.
Sebastian VoigtInstitute of Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Marie von Lilienfeld-ToalInstitute for Diversity Medicine, Ruhr University Bochum, Bochum, Germany.
Daniel TeschnerDepartment of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Oliver A CornelyInstitute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
Christina RiegerHematology Oncology Germering, Germering, Germany.
Elena BuschInternal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Community-acquired respiratory viruses (CARV), such as influenza-, parainfluenza- or respiratory syncytial virus, pose a significant threat to immunocompromised patients with cancer. Following the COVID-19 pandemic, SARS-CoV-2 has now joined the ranks of endemic respiratory viruses and continues to be a cause of significant morbidity and mortality in patients with cancer. Strategies to protect this vulnerable patient population both by prevention of infection and by early therapeutic intervention in case of infectious disease are therefore of utmost importance. This guideline provides updated evidence-based recommendations on diagnosis, prophylaxis and treatment of CARV infections including COVID-19 in patients with solid tumors or hematologic malignancies to support clinicians in offering optimal care. The guideline is based on a systematic review of currently available data and was developed until the beginning of 2025 by an expert panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).

Indexed as

Community-Acquired InfectionsCOVID-19NeoplasmsRespiratory Tract InfectionsEvidence-Based MedicineGermanyHematologyHumansImmunocompromised HostMedical OncologySocieties, MedicalCancerCOVID-19GuidelineHematologic malignancyInfluenzaRespiratory syncytial virusRespiratory virusSARS-CoV-2Solid tumor

Identifiers

PMID41563477
PMCPMC12823726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.